Technology

Next Science is leading a paradigm shift with a unique, unprecedented approach to eradicating both biofilm bacteria and planktonic bacteria with a proprietary, non-toxic technology that disrupts the biofilm’s extracellular polymeric substance (EPS) matrix and makes the bacteria within the biofilm more vulnerable to attack by antimicrobials, antibiotics and the body’s natural immune defenses. This patented Xbio technology may help reduce the overall use of antibiotics and has shown no known evidence of bacterial resistance.29

Powerful. Gentle. Innovative.

Next Science believes in a healthcare world where the toughest microbial infections (bacterial, fungal, viral) are treated effectively and the microbes are unable to evade eradication through biofilms.
Additionally, treating infections should be gentle on the body and nontoxic to the environment.

 

Mechanism of Action

Next Science’s Xbio uses proprietary composition-of-matter patents that contain technology to physically break down the biofilm’s protective structures, exposing and eradicating bacteria through cell lysis.

<- Watch the video for more

Revolutionary Results

Drawing on an extensive background in material science, Next Science is the leader in biofilm solutions with multiple in vitro and in vivo scientific and clinical studies, thorough safety testing, and effective technology delivery systems. Comprehensive and continuous research over time, applied to multiple applications, has resulted in the development of the most effective products for the disruption of biofilm.

Unlike other agents that claim to destroy biofilms, there is no known resistance to Next Science technology; variants are effective against any bacteria, persister cells or spores, and reduce the rate of biofilm recurrence over 100 times. 39

Limitless Potential

Next Science has created a rapid-acting technology with superior efficacy for both planktonic and biofilm bacterial forms. Xbio is gentle, has low toxicity and has a favorable environmental impact. Learn more about our pipeline opportunities and how we are addressing the growing problem of biofilm-caused antimicrobial resistance.